 Announced new positive data in human experimental model of inflammation of EDP1815Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021Up to 8 clinical data readouts expected over next 18 monthsManagement to host conference call at 8:30 a.m. ET 